NGS and TME for Evidence-based Treatment of Pancreatic Cancer

Inclusion Criteria: * Patient age ≥ 18 years up to 75 years * Patient willing and able to provide informed consent * TreatmentMAP™ NGS/TME is ordered by the tumor board (MDT) under routine clinical practice * Diagnosis of a locally advanced, inoperable or metastatic pancreatic carcinoma, clinically and histologically verified according to the currently prevailing standards. * Patient received first line therapy according to applicable guidelines and/or standards (SoC) * Sufficient testing material available (e.g. tumor biopsy) to allow NGS/TME NGS panel testing. Exclusion Criteria: * Patients with ongoing systemic infection, * Patients with immunodeficiency, * Patients with severe cardiovascular and pulmonary morbidity that might interfere with or preclude further systemic anticancer treatment, * Patients on full therapeutic anticoagulation. * Patients who, due to their clinical status, are not eligible for further systemic anticancer therapy (chemotherapy, immunotherapy etc.) * Patients who, due to their disease status are in need of immediate therapy and cannot wait for the result of the NGS/TME process.